Actelion Reports Further Progress to Additional Markets for Tracleer in Pulmonary Arterial Hypertension
15 déc. 2003 01h14 HE
|
Actelion Ltd.
ALLSCHWIL and BASEL, Switzerland, Dec. 15, 2003 (PRIMEZONE) -- Actelion:
-- Reimbursement status achieved in Australia
-- Labeling questions received from Japanese regulator
-- Limited...
Actelion and Merck Form Renin Inhibitor Alliance
04 déc. 2003 01h19 HE
|
Actelion Ltd.
ALLSCHWIL/BASEL, Switzerland and WHITEHOUSE STATION, N.J., Dec. 04, 2003 (PRIMEZONE) -- Actelion:
-- Actelion to advance its break-through discoveries of new classes
of renin inhibitors...
Actelion presents its Research and Development efforts
29 oct. 2003 01h14 HE
|
Actelion Ltd.
ALLSCHWIL/BASEL, Switzerland, Oct. 29, 2003 (PRIMEZONE) -- Actelion Ltd (SWX:ATLN) today provided a comprehensive overview of its preclinical and clinical pipeline at its R&D Day in London (UK)....
Actelion announces 9-month results for 2003
28 oct. 2003 01h33 HE
|
Actelion Ltd.
ALLSCHWIL/BASEL, Switzerland, Oct. 28, 2003 (PRIMEZONE) -- Actelion (SWX:ATLN) (Other OTC:ALIOF)
-- Strong Tracleer(R) sales in Pulmonary Arterial Hypertension
result in an operating profit...
Actelion Ltd. Invitation to webcast and conference call
23 oct. 2003 10h54 HE
|
Actelion Ltd.
ALLSCHWIL, Switzerland, Oct. 23, 2003 (PRIMEZONE) -- Actelion announces the 9 months 2003 results on 28th October 2003.
Actelion Research and Development Day 2003 on 29th October 2003
Dear Friend...
Actelion acquires privately held Axovan AG: Integration will strengthen both late-stage development pipeline and early drug discovery efforts
30 sept. 2003 01h27 HE
|
Actelion Ltd.
ALLSCHWIL/BASEL, Switzerland, Sept. 30, 2003 (PRIMEZONE) --
- Actelion to further develop intravenous endothelin receptor
antagonist optimized for cerebral indications currently in
Phase...
HIV Patients with Pulmonary Arterial Hypertension (PAH): Results of Treatment with Oral Tracleer (bosentan)
02 sept. 2003 01h57 HE
|
Actelion Ltd.
ALLSSHWIL, Switzerland, Sept. 02, 2003 (PRIMEZONE) -- Actelion Ltd (SWX:ATLN) (Other OTC:ALIOF) today announced results of a study assessing its oral dual endothelin receptor antagonist (ERA)...
US Food and Drug Administration approves Zavesca
01 août 2003 02h35 HE
|
Actelion Ltd.
ALLSCHWIL/BASEL, July 31, 2003 (PRIMEZONE) -- Actelion Ltd (SWX: ATLN) today announced that the US Food and Drug Administration (FDA) has approved Zavesca(r) (miglustat) capsules the first oral...
Actelion Ltd. and Axovan AG Enter Research Collaboration
17 juin 2003 01h47 HE
|
Actelion Ltd.
ALLSCHWIL/BASEL, Switzerland, June 17, 2003 (PRIMEZONE) -- Actelion Ltd. (SWX:ATLN) and privately held Axovan AG announced today that they have entered into a research collaboration. The two...
Actelion to further strengthen its research efforts
02 juin 2003 17h11 HE
|
Actelion Ltd.
ALLSCHWIL/BASEL, Switzerland/SAN DIEGO, , June 02, 2003 (PRIMEZONE) -- Actelion Ltd (SWX:ATLN) and Discovery Partners International, Inc. (Nasdaq:DPII) today announced that the two companies have...